| Summary: | Developments in biotechnology in recent years have enabled the discovery of new pharmacological agents for the treatment and prophylaxis
of infectious diseases. The agents obtained from these biotechnological procedures possess specific characteristics which significantly distinguish
them from drugs obtained by chemical synthesis. These properties cover the entire development process, from investigation and production
up to their administration to patients. The pharmokinetics of these preparations influence their administration routes and dosage regimens.
The discovery of these drugs has led to major advances in the treatment and prophylaxis of infectious processes which until very recently
had no effective treatment. The investigation and production of these drugs requires the use of highly technical resources resulting in
high costs and therefore a more expensive drug on the market compared to other drugs. Nevertheless, well documented pharmoeconomic
studies show that the use of this type of drug for certain symptoms may be highly cost effective. This article includes some of the possible applications
of biotechnology in the infectious disease field, although the current situation indicates that more detailed and broader applications
may be elaborated on in ensuing issues. The future of these drugs in chemical therapy for the treatment and prophylaxis of infectious diseases
is exceedingly promising and many of these drugs are currently under laboratory investigation, more so than those under development
from a chemical synthesis approach.
|
|---|